Human recombinant lysozyme downregulates advanced glycation endproduct-induced interleukin-6 production and release in an in-vitro model of human proximal tubular epithelial cells

Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy

(2011) Juan F. Navarro-González et al.   Nature Reviews Nephrology

Characterization of Bioactive Recombinant Human Lysozyme Expressed in Milk of Cloned Transgenic Cattle

(2011) Bin Yang et al.   PLoS One

Advanced glycation end products inhibit Na+ K+ ATPase in proximal tubule epithelial cells: Role of cytosolic phospholipase A2α and phosphatidylinositol 4-phosphate 5-kinase γ

(2010) Marisa A. Gallicchio et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH

Advanced glycation end products induce chemokine/cytokine production via activation of p38 pathway and inhibit proliferation and migration of bone marrow mesenchymal stem cells

(2010) Ke Yang et al.   Cardiovascular Diabetology

Receptor for advanced glycation end-products (RAGE) and soluble RAGE (sRAGE): cardiovascular implications

(2009) Jason B Lindsey et al.   Diabetes & Vascular Disease Research

RAGE-Induced Cytosolic ROS Promote Mitochondrial Superoxide Generation in Diabetes

(2009) M. T. Coughlan et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Orally administered microencapsulated lysozyme downregulates serum AGE and reduces the severity of early-stage diabetic nephropathy

(2008) M. Cocchietto et al.   DIABETES & METABOLISM

The Role of Advanced Glycation End Products in Progression and Complications of Diabetes

(2008) Su-Yen Goh et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Skin autofluorescence is increased in systemic lupus erythematosus but is not reflected by elevated plasma levels of advanced glycation endproducts

(2008) H. L. Nienhuis et al.   RHEUMATOLOGY